A Seaweed Solution: New Trial Shows Natural Extract Eases Prostate Woes

HOBART, Australia – July 27, 2026 – For the millions of men who experience the disruptive symptoms of an enlarged prostate, relief may come from an unlikely source: the ocean. A groundbreaking clinical trial has revealed that a high-purity extract from brown seaweed, known as fucoidan, can significantly and safely alleviate the symptoms of benign prostatic hyperplasia (BPH).

The findings, published in the peer-reviewed journal Research and Reports in Urology, present a formidable new contender in the men's health space, offering a natural alternative backed by the rigor of a randomized, double-blind, placebo-controlled study—the gold standard in clinical research. For a condition that affects more than half of men in their 60s and up to 90% of those in their 80s, this development could dramatically improve the quality of life for a vast and growing population.

A Clinically Significant Breakthrough

The study, spearheaded by Australian biotechnology company Marinova, provides compelling evidence for a compound that has, until now, remained largely under the clinical radar for prostate health. “To date, very few natural compounds have been clinically studied and shown to support prostate health effectively,” said lead researcher Dr. Barbara Wimmer. “The documented bioactivities of fucoidan led us to embark on this groundbreaking trial.”

Over 90 days, researchers tracked 88 men aged 45 to 80 with moderate BPH. One group received a daily 1-gram dose of the high-purity fucoidan supplement, while the other received a placebo. The results were not just statistically significant; they were clinically meaningful, a distinction that matters greatly to both patients and practitioners.

Using the globally recognized International Prostate Symptom Score (IPSS) to measure changes, the study reported remarkable improvements in the fucoidan group compared to placebo:

• A more than nine-fold improvement in voiding symptoms, which include common frustrations like a weak stream, straining, and the sensation of incomplete emptying.
• A two-fold improvement in storage symptoms, such as urinary frequency, urgency, and disruptive nighttime urination (nocturia).
• A clinically significant reduction in overall BPH symptoms and a corresponding improvement in quality of life.

Crucially, the fucoidan supplement was well-tolerated and demonstrated an excellent safety profile. Unlike some pharmaceutical options, it showed no negative side effects. Furthermore, it did not alter levels of prostate-specific antigen (PSA), a key biomarker used in prostate cancer screening, ensuring that its use would not interfere with routine and critical health monitoring.

Reshaping the BPH Treatment Landscape

The current landscape for BPH management is a trade-off. Standard pharmaceutical treatments, such as alpha-blockers and 5-alpha reductase inhibitors (5-ARIs), can be effective but often come with a list of undesirable side effects, including dizziness, fatigue, and sexual dysfunction. On the other end of the spectrum, the natural supplement market is flooded with options, most notably saw palmetto, but their efficacy is often debated, with major clinical reviews showing inconsistent results that are sometimes no better than a placebo.

Marinova's fucoidan trial enters this arena with a clear advantage: robust, peer-reviewed data. The reported 28% reduction in IPSS scores for the fucoidan group significantly outperforms the 16% reduction often cited in studies of saw palmetto oil. This positions the seaweed extract not merely as another supplement, but as an evidence-based nutraceutical that could bridge the gap between less-proven natural remedies and pharmaceuticals with known side effects.

This provides a new pathway for men who are hesitant to start pharmaceutical treatment, are experiencing side effects from their current medication, or are simply seeking a safe, natural, and effective way to manage their symptoms. As one independent urology researcher noted, the combination of clinical efficacy and a strong safety profile is the 'holy grail' for managing chronic, non-life-threatening conditions like BPH.

The Science of Seaweed

Fucoidan is not a new discovery, but its application in BPH is a novel and strategic innovation. The compound, a sulfated polysaccharide, has long been studied for its potent anti-inflammatory, antioxidant, and immunomodulatory properties. These underlying bioactivities provide a plausible scientific basis for its effectiveness in BPH, a condition increasingly understood to have a significant inflammatory component.

Marinova’s research director, Dr. Wimmer, suggests the mechanism is likely multifactorial. The company’s own pre-clinical animal study, published in 2024, showed fucoidan reduced prostate weight and key hormone levels in rats, pointing to anti-inflammatory and pro-apoptotic (promoting the death of abnormal cells) effects. Emerging science also points to a 'gut-prostate axis,' and fucoidan is known to support gut health by promoting beneficial bacteria and the production of short-chain fatty acids like butyrate, which have system-wide anti-inflammatory benefits.

This deep scientific underpinning is a hallmark of Marinova, a company that has built its reputation on transforming a natural marine ingredient into a high-value, scientifically validated product. The firm uses a proprietary aqueous extraction process to produce its certified-organic fucoidan, ensuring a high-purity compound free from the harsh solvents that can compromise quality. This commitment to quality and research sets a high bar in the often-unregulated supplement industry.

From Australian Biotech to Global Men's Health

With these compelling trial results, the path is now clear for commercialization. The Tasmanian-based company is not planning to launch its own consumer-facing brand. Instead, its strategy is to supply its premium, clinically validated Maritech® fucoidan ingredient to leading nutraceutical companies around the world, enabling them to formulate new, evidence-backed men's health products.

This business model leverages the company's core strengths in research, development, and high-purity manufacturing. It also accelerates market access, as Marinova's fucoidan already boasts an impressive portfolio of global regulatory approvals, including FDA GRAS (Generally Recognized As Safe) status in the USA, and approvals for use in Australia, Canada, Europe, and China.

For the millions of men quietly navigating the daily challenges of BPH, this Australian innovation represents more than just another supplement. It signifies a shift towards a new generation of natural health solutions—ones that are not only inspired by nature but are also rigorously tested, proven safe, and genuinely effective.